Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib or Enasidenib plus Azacitidine in IDH-mutant AML
NCT02677922Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jun 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of ivosidenib, enasidenib in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Jun 2016; status: active, not recruiting.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02677922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677922.